Which has the lower trailing P/E, GMED or UHS?

UHS has the lower trailing P/E: GMED trades at 21.22 and UHS at 7.08. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, GMED or UHS?

Over the past five years, GMED grew revenue faster — GMED at a 27.65% CAGR versus UHS at 8.21%.

Does GMED or UHS pay a bigger dividend?

UHS pays a dividend (0.46% yield), while GMED has no payments in the available dividend history.

Is GMED or UHS more profitable?

GMED runs the higher net margin — GMED at 17.03% versus UHS at 8.42%.

How have GMED and UHS total returns compared?

Over the past 10 years, GMED delivered 13.76% and UHS delivered 4.20% annualized total return. Past performance doesn't predict future results.

Globus Medical, Inc. (GMED) vs Universal Health Services, Inc. (UHS)

A side-by-side comparison of Globus Medical, Inc. and Universal Health Services, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 28, 2026. Differences are shown without an overall score or investment verdict.

GMED

Globus Medical, Inc.

$11.13B

$82.54HealthcareDelayed quote: Aug 27, 2026, 4:00 PM EDT

UHS

Universal Health Services, Inc.

$10.45B

$172.58HealthcareDelayed quote: Aug 27, 2026, 4:00 PM EDT

Total return — GMED vs UHS

growth of $100 · dividends reinvested · last 10y

GMED +257.6% (+13.6%/yr)UHS +49.7% (+4.1%/yr)GMED compounded faster over this window

GMED UHS

GMED vs UHS: by the numbers

•GMED is the larger company ($11.13B vs $10.45B market cap).
•UHS trades at the lower trailing earnings multiple (7.08 vs 21.22 P/E), one valuation lens rather than an overall verdict.
•GMED converts more revenue to profit (17.03% vs 8.42% net margin).
•GMED grew revenue faster over the past five years (27.65% vs 8.21% CAGR).
•UHS pays a dividend (0.46% yield), while GMED has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	GMED	UHS
P/E ratio	21.22	7.08
Forward P/E	16.57	7.65
P/S ratio	3.63	0.57
P/B ratio	2.39	1.38
EV / EBITDA	11.79	5.73
FCF yield	6.58%	7.99%

Profitability

Metric	GMED	UHS
Gross margin	68.55%	90.69%
Operating margin	20.75%	11.36%
Net margin	17.03%	8.42%
ROE	11.23%	20.31%
ROIC	10.49%	11.74%

Dividends

Metric	GMED	UHS
Dividend yield	N/A	0.46%
Payout ratio	N/A	3.42%

Growth (annualized)

Metric	GMED	UHS
Revenue CAGR (5Y)	27.65%	8.21%
EPS CAGR (5Y)	30.79%	16.19%
FCF CAGR (5Y)	29.93%	-12.18%
Total return CAGR (5Y)	0.22%	2.47%

Frequently asked

Which has the lower trailing P/E, GMED or UHS?: UHS has the lower trailing P/E: GMED trades at 21.22 and UHS at 7.08. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, GMED or UHS?: Over the past five years, GMED grew revenue faster — GMED at a 27.65% CAGR versus UHS at 8.21%.
Does GMED or UHS pay a bigger dividend?: UHS pays a dividend (0.46% yield), while GMED has no payments in the available dividend history.
Is GMED or UHS more profitable?: GMED runs the higher net margin — GMED at 17.03% versus UHS at 8.42%.
How have GMED and UHS total returns compared?: Over the past 10 years, GMED delivered 13.76% and UHS delivered 4.20% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GMED analysis Full UHS analysis Interactive comparison tool

Dig into the metrics

Globus Medical P/E ratio Universal Health Services P/E ratio Universal Health Services dividend yield Globus Medical ROE Universal Health Services ROE Globus Medical operating margin Universal Health Services operating margin Globus Medical revenue growth Universal Health Services revenue growth Globus Medical free cash flow Universal Health Services free cash flow

Globus Medical & Universal Health Services appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 28, 2026.